We have re-examined the evidence on which current British Thoracic Society recommendations for primary and secondary prophylaxis and therapy of tuberculosis are based. We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to tuberculin positive or anergic patients from high-incidence groups, including immigrants from high-prevalence countries, intravenous drug users and those with previous tuberculosis, that secondary prophylaxis be witheld from all but very high-risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance. (Genitourin Med 1996;72:89-92) 
Introduction
There is no doubt that tuberculosis (TB) is a major problem worldwide within the context of HIV but there are fewer data from countries with a low prevalence of tuberculosis, such as the UK, on which to base informed decisions. The British Thoracic Society has recently produced guidelines on the Control and prevention of tuberculosis in the United Kingdom' which were published in the journal Thorax. In the previous month's issue there was a signed editorial from some of the members of the British Thoracic Society Tuberculosis sub-committee entitled Tuberculosis in the UK 1994; Current issues and future trends.' Along with the 1992 British Thoracic Society's paper Guidelines on the management of tuberculosis and HIV infection in the United Kingdom3 these articles provide the British Thoracic Society's opinion on the management of tuberculosis in HIV positive patients in the UK, including case finding, contact tracing, chemoprophylaxis and use of BCG vaccination. They will also act as a source of information for physicans working outside the UK who may well be influenced by these recommendations. In this article we look critically at currently available information and offer an alternative interpretation of the data with particular reference to countries with a low prevalence of tuberculosis.
Primary chemoprophylaxis for tuberculosis There is a great deal of accumulated evidence to show that isoniazid, usually given at a daily dose of 300 mg for 12 months, significantly reduces the subsequent incidence of TB in patients at high risk for this disease.-9 The highest rate of protection was reported in a study from Haiti4 in patients who were tuberculin positive, with a reduction from 10 to 1.7 cases of TB per 100 patient years follow-up. TB developed in a total of six of the twenty five (24%) tuberculin positive patients without prophylaxis wheras only two of thirty eight (5%) patients given prophylaxis went on to develop TB. However, Haiti is a country with a high prevalence of TB and a low rate of BCG vaccination in the adult population and taken together with the facts that a high proportion of the trial subjects were women (77%) and follow-up of participants was variable (3-60 months), it makes these data difficult to interpret and apply to conditions where TB is less prevalent and where the majority of patients are men.
Primary isoniazid prophylaxis has also been successful in other countries with a high prevalence of TB including Spain, Italy and the US, although results have been less dramatic and the studies sometimes less well designed.5-9 The crucial elements for successful primary prophylaxis include a population with a significant risk for TB (which 13 18 Should primary isoniazid prophylaxis be offered to HIV-positive patients in the UK and other countries with a low prevalence of TB? The 1992 British Thoracic Society guidelines were in favour of primary prophylaxis and gave detailed instructions on how to identify suitable patients,' although the advice in the 1994 paper has changed to that of the risks and benefits (of primary prophylaxis) remain to be determined.2 There are three main problems regarding the use of prophylaxis in countries with a low prevalence of TB. Firstly, where BCG immunisation has been used extensively, as in the UK, then tuberculin testing is far more difficult to interpret with regard to previous exposure to TB '9 and there are no published data on the interpretation of tuberculin testing in BCG vaccinated HIV-positive patients. Identification of patients who might benefit from prophylaxis therefore becomes much more difficult. Secondly, there are few accurate data on the incidence of TB in the HIV positive population in the UK. One UK-based study suggested that 6% of HIV patients will develop TB but this estimate was based on a group of patients selected on the basis of either already having AIDS or who were in a cohort being studied for mycobacteria in stool.20 A report from the Communicable Diseases Surveilance Centre using data that are incomplete (because of the under-reporting of AIDS and the failure to report tuberculosis unless it was the first AIDSdefining condition), reported a 4.6% incidence tuberculosis in AIDS patients. '9 There are no prospective data in the UK of HIV testing in TB patients although the national survey of 1993-4 may provide this information when published. Thirdly, the published studies of isoniazid prophylaxis were in populations with a prevalence of tuberculosis (evidence of previous exposure) of between 20% and 50%. There are no such studies in populations with a lower background prevalence, such as the UK.
Given the low prevalence of TB, the uncertainties surrounding the interpretation of the tuberculin reaction and the rate of isoniazidrelated side effects, there appears to be little evidence to support a policy of routine screening and primary prophylaxis in HIV-positive patients born in countries with a low rate of TB, especially for patients who have had BCG vaccination. Patients who may benefit from a screening and prophylaxis programme, if the 4-8% risk of severe isoniazid toxicity is acceptable, would be immigrants from countries with a prevalence of tuberculosis, including people who have lived or worked there for prolonged periods (> 6 months), those with a past history of tuberculosis and injection drug users. 5 19 Diagnosis and Management of Tuberculosis Much has been written about the spectrum of disease caused by M Tuberculosis in HIV infected individuals. 16 17 21-24 In summary, the presentation of pulmonary tuberculosis that is typical of disease in non-HIV-infected patients with fever, cough and haemoptysis and apical/cavitatory disease on chest radiography is seen much less commonly in HIV-positive patients and is largely restricted to those with higher CD4+ lymphocyte counts. There is a greater incidence of extra-pulmonary disease in HIV-positive patients, occurring in approximately 60%, a third of whom will also have pulmonary disease.'622 Pulmonary parenchymal disease is often widespread and interstitial.'72' The chest radiograph may be normal in between 5% and 20% of pulmonary disease.2' There is a much lower rate of sputum positivity for acid fast bacilli in pulmonary disease (60%) and so the diagnosis is more frequently confirmed by bronchoscopy, culture and histology.'6172122 There is a much higher mortality rate for HIV infected patients with TB as compared with HIV-negative patients. Small et al reported that 44% of 132 patients with HIV and TB died before their TB therapy was completed, but the excess deaths were usually related to other AIDS-related problems, with only 6.4% dying from TB. '6 Response to standard anti-mycobacterial chemotherapy is very good with a rate of resolution of clinical features and loss of sputum positivity comparable with that seen in in HIV-negative patients'6 17 25 The rate of relapse after standard therapy is also very low and therefore there is no need to extend therapy beyond six months. In one study, relapses were only seen after inadequate therapy due to patient non-compliance and occured in 5% of patients, all relapses being detected within 3 months of cessation of therapy. 6 What is standard chemotherapy? The tuberculosis sub-committee of the British Thoracic Society suggest a triple regimen of rifampicin, isoniazid and pyrazinamide given for two months, followed by rifampicin and isoniazid for a further four months, with the addition of ethambutol in the first two months only if there is a significant rate of drug resistance locally or the patient has been previously treated abroad. 2 seven of these within two months. 30 Another report shows that exposure to patients with smear-positive tuberculosis need only be brief for HIV positive-patients to become infected. In that study a case cluster of tuberculosis was caused by a single strain of M tuberculosis, where the index case was only briefly in contact on the same ward with the two patients who were subsequently infected." Recent studies also reveal that approximately 60% of tuberculosis in HIV-positive patients in the US is due to secondary infection rather than reactivation whereas only 10 to 20% of tuberculosis in non-HIV-infected adults in developed countries is due to secondary infection.'23' In the light of this evidence of increased susceptibility of HIVpositive patients to developing active tuberculosis after minimal exposure to M Tuberculosis, we suggest that as well as isolating all patients with pulmonary tuberculosis diagnosed by sputum microscopy, those diagnosed by microscopy of BAL fluid should also be isolated in a sideroom if there are other HIV-positive patients on the ward, until they have received at least two weeks anti-tuberculosis therapy.
We also have a duty of responsibility to HIVinfected health care workers who are also at significant risk of acquiring tuberculosis when caring for infected patients. National guidelines for HIV-infected health care workers advise that they be given duties that would not put them in a position where they pose an infectious risk to 
